Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

Background: Cladribine, an oral prodrug, penetrates the blood–brain barrier, impacting biomarkers of disease progression within the central nervous system. Objectives: Describe disease activity in cladribine tablets (CladT)-treated people with highly active relapsing multiple sclerosis (pwRMS) using...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Finn Sellebjerg, Patrick Vermersch, Hulin Jin, Laura Sponton, Anita Chudecka, Lidia Gardner, Nicola De Stefano
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864251351760
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562864251351760

Similar Items